

DAFTAR PUSTAKA

- Alamri, K. N. H., Posangi, J., & Nangoy, E. (2021). Perbandingan Efektivitas Penggunaan Donepezil dan Memantine Terhadap Perbaikan Fungsi Kognitif pada Penyakit Alzheimer. *Jurnal Biomedik (Jbm)*, 13(2), 218. <https://doi.org/10.35790/jbm.13.2.2021.31950>
- ARICEPT. (2021). This label may not be the latest approved by FDA. For current labeling information, please visit <https://www.fda.gov/drugsatfda>. Woodcliff Lake, NJ; Eisai Inc, 2010, 4–8.
- ASHP. (2024). Donepezil (Monograph). Medically reviewed by Drugs.com on Oct 30, 2024.
- Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C., & Hassenstab, J. J. (2018). Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*, 91(9), e859–e866. <https://doi.org/10.1212/WNL.0000000000006075>
- Birks, J. S., & Harvey, R. J. (2018). Donepezil for dementia due to Alzheimer's disease. *Cochrane Database of Systematic Reviews*, (6), CD001190. <https://doi.org/10.1002/14651858.CD001190.pub3>
- Bryson, H. M., & Benfield, P. (1997). Donepezil. *Drugs & Aging*, 10(3), 234–240. <https://doi.org/10.2165/00002512-199710030-00007>
- Chadha, V. K. (2006). Sample size determination in health studies. 55–62.
- Charidimou. (2022). The Boston Criteria v2.0 for cerebral amyloid angiopathy: A multicentre MRI-neuropathology diagnostic accuracy study. *Physiology & Behavior*, 176(1), 100–106. <https://doi.org/10.1177/0022146515594631.Marriage>
- Chen, J. H., Lin, K. P., & Chen, Y. C. (2009). Risk factors for dementia. *Journal of the Formosan Medical Association*, 108(10), 754–764. [https://doi.org/10.1016/S0929-6646\(09\)60402-2](https://doi.org/10.1016/S0929-6646(09)60402-2)
- Chin, K. S. (2023). Pathophysiology of dementia. *Brain and Nerve*, 37(10), 931–943.
- Chowdhary, N., Barbui, C., Anstey, K. J., Kivipelto, M., Barbera, M., Peters, R., Zheng, L., ... Dua, T. (2022). Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations. *Frontiers in Neurology*, 12, 1–7. <https://doi.org/10.3389/fneur.2021.765584>
- Clodomiro, A., Gareri, P., Puccio, G., Frangipane, F., Lacava, R., Castagna, A., ... Bruni, A. C. (2013). Somatic comorbidities and Alzheimer's disease treatment. *Neurological Sciences*, 34(9), 1581–1589. <https://doi.org/10.1007/s10072-013-1290-3>

- Deltani, D. (2024). The effect of donepezil and hyosiamoside on improving spatial memory in rats with Alzheimer's disease. *3(3)*, 950–971.
- Dewi, S. U., & Rahmawati, P. A. (2019). Penerapan Terapi Rendam Kaki Menggunakan Air Hangat Dalam Menurunkan Tekanan Darah. *JIKO*, *3(2)*, 74–80. <https://doi.org/10.46749/jiko.v3i2.33>
- Diseases, K. (2019). Adverse Drug Reaction Probability Scale (Naranjo). National Institutes of Health, U.S. Dept. of Health & Human Services, May, 1–5.
- Fitriantoro, S., Harahap, H. S., Landapa, R. R., Suryani, D., Prita, B., ... Studi, P. (2024). Education on Alzheimer's Disease for Neurology Clinic Visitors at The Provincial General. *11*, 3048–3055.
- Hapsari, M. Y. A., Baihaqy, F. T., Ilyas, M. F., Budianto, P., & Novika, R. G. H. (2023). Effects of acetylcholinesterase inhibitor Donepezil on cognitive function and vital sign in patients with dementia. *Jurnal Kedokteran Syiah Kuala*, *23(1)*, 1–6. <https://doi.org/10.24815/jks.v23i1.27558>
- Huang, L., & Aronow, W. S. (2024). Association of Hypertension with Different Cognitive Disorders. *Stomatology*, *13(20)*, 6029. <https://doi.org/10.3390/jcm13206029>
- Ian G. McKeith, M., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J. P., ... Psych, M. (2017). Diagnosis and management of dementia with Lewy bodies. *Neurology*, *25(11)*, 923–927.
- Ji, H., Ebinger, J. E., Kwan, A. C. Y., Reue, K., Sullivan, J. C., Shyy, J., & Cheng, S. (2024). Early-Onset Hypertension and Sex-Specific Residual Risk for Cardiovascular Disease in Type 2 Diabetes. *Diabetes Care*. <https://doi.org/10.2337/dc23-2275>
- Jia, J., Wei, C., Jia, L., Tang, Y., Liang, J., Zhou, A., Li, F., ... Doody, R. S. (2017). Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease. *Journal of Alzheimer's Disease*, *56(4)*, 1495–1504. <https://doi.org/10.3233/JAD-161117>
- Keefe, R. S. E., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A., Sovel, M., Li, C., & Goldman, R. (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. *Neuropsychopharmacology*, *33(6)*, 1217–1228. <https://doi.org/10.1038/sj.npp.1301499>
- Kluzek, S., Dean, B., & Wartolowska, K. A. (2022). Patient-reported outcome measures (PROMs) as proof of treatment efficacy. *BMJ Evidence-Based Medicine*, *27(3)*, 153–155. <https://doi.org/10.1186/1477-7525-4-1>
- Kumar, A., Gupta, V., & Sharma, S. (2023). Donepezil. StatPearls. Treasure Island (FL): StatPearls Publishing.

- Lane, C. A., Hardy, J., & Schott, J. M. (2020). Alzheimer's disease Christopher. *Nature Reviews Disease Primers*, 4(274), 1–9.
- Li, D.-D., Zhang, Y.-H., Zhang, W., & Zhao, P. (2019). Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease. *Frontiers in Neuroscience*, 13, 472. <https://doi.org/10.3389/fnins.2019.00472>
- Lin, Y. T., Hwang, T. J., Shan, J. C., Chiang, H. L., Sheu, Y. H., & Hwu, H. G. (2015). Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. *Journal of the Formosan Medical Association*, 114(2), 147–153. <https://doi.org/10.1016/j.jfma.2012.09.002>
- Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet*, 396(10248), 413–446.
- Lou, H., Jiang, Y., Xu, C., Dong, Z., De, L., Qiao, C., & Zhang, P. (2024). Effects of a combination of dyslipidemia and hypertension on the glycemic control of patients with type 2 diabetes mellitus: a cross-sectional study. *Sage Open Medicine*, 12. <https://doi.org/10.1177/20503121241265066>
- Lyon, M., Fullerton, J. L., Kennedy, S., & Work, L. M. (2024). Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden. *Pharmacology and Therapeutics*, 253, 108575. <https://doi.org/10.1016/j.pharmthera.2023.108575>
- Mahandra, B. A., Tadjudin, N. S., Astungkari, A. D., Setyaningrum, O., Ardena, B., Vidheashinta, V., ... Tarumanagara, U. (2024). Cara mendiagnosis demensia Alzheimer dengan kriteria DSM-V. *Case Report*, 4(2), 142–147.
- Noetzli, M., & Eap, C. B. (2013). *Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease*. *Clinical Pharmacokinetics*, 52(4), 225–241.
- Notoatmodjo. (2019). *Promosi Kesehatan dan Ilmu Perilaku* (Vol. 4, Issue 12). Rineka Cipta.
- Odenigbo, N., Nkemjika, S., Atolagbe, A., Nwabueze, C., Olwit, C., Lawrence, J., & Olupona, T. (2024). Donepezil-induced bradycardia in a schizophrenic patient with comorbid neurocognitive disorder: a case report and review of the literature. *Journal of Medical Case Reports*, 18(1), 1–4. <https://doi.org/10.1186/s13256-024-04454-x>
- Otani, N., Kanda, K., Ngatu, N. R., Murakami, A., Yamadori, Y., & Hirao, T. (2024). Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER). *Medicina (Kaunas)*, 60(10), 1633. <https://doi.org/10.3390/medicina60101633>

- Papakyriakopoulou, P., Valsami, G., & Dev, K. K. (2024). The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease. *Molecular Neurobiology*, 61(11), 8688–8701. <https://doi.org/10.1007/s12035-024-04137-0>
- Pasi, I. R. (2017). Pengaruh Pengetahuan dan Sikap Terhadap Perilaku Masyarakat pada Bank Syariah. *Jurnal Al-Qasd*, 1(2), 4.
- Prabowo, D. A., & Chondro, F. (2021). Hubungan konsumsi susu dengan fungsi kognitif pada lansia. *Jurnal Biomedika dan Kesehatan*, 4(4), 148–156. <https://doi.org/10.18051/jbiomedkes.2021.v4.148-156>
- Pramana, I. D. B. K. W., & Harahap, H. S. (2020). Manfaat kualitas tidur yang baik dalam mencegah demensia pada lansia. *Lombok Medical Journal*, 1(1), 49–52.
- Rahmayati, S., Sakhnan, R., Rusdi, I., & Forwaty, E. (2024). Application of Brain Gym Therapy to Improve Cognitive Function in Elderly With Dementia Problems. 3(1), 35–56.
- Roca, R. M., García-Gutiérrez, F., Cantero-Fortiz, Y., et al. (2025). Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit. *Alzheimer’s Research & Therapy*, 17, 27. <https://doi.org/10.1186/s13195-024-01656-9>
- Rosende-Roca, M., Abdelnour, C., Esteban, E., Tartari, J. P., Alarcon, E., Martínez-Atienza, J., ... Boada, M. (2021). The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening. *Alzheimer’s Research & Therapy*, 13(1), 1–13. <https://doi.org/10.1186/s13195-021-00833-4>
- Sabbagh, M. N., Hendrix, S., & Harrison, J. E. (2020). *FDA-approved therapies for Alzheimer’s disease: A practical guide for the clinician*. *Alzheimer’s & Dementia: Translational Research & Clinical Interventions*.
- Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., ... Scheltens, P. (2014). Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. *Alzheimer Disease and Associated Disorders*, 28(3), 206–218. <https://doi.org/10.1097/WAD.0000000000000034>
- Sari, L. K., & Hilmi, I. L. (2022). Peningkatan Demensia melalui Rokok: Literature Review. *Farmasetis*, 11(3), 195–200. <http://journal2.stikeskendal.ac.id/index.php/far/article/view/494/432>
- Sheikh, M., & Ammar, M. (2024). Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. *Frontiers in Neuroscience*, 18. <https://doi.org/10.3389/fnins.2024.1398952>
- Shen, Y., Timsina, J., Heo, G., Beric, A., Ali, M., Wang, C., ... Sung, Y. J. (2024). CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease. *Cell*, 187(22), 6309–6326.e15.

<https://doi.org/10.1016/j.cell.2024.08.049>

Siswo, P., Arsyad, N., Susilowati, D., Waluyo, I., Isra, A., ... Saraf RSUD Cengkareng Jakarta Barat, S. (2013). Perbedaan Riwayat Jatuh Berdasarkan Kognitif dan Atensi Antara Lansia. 3, 1–15.

Sugiyono. (2020). Metode Penelitian Kuantitatif, Kualitatif dan R&D. Alfabeta.

Suyamto, S. (2022). Program Preventif Pengendalian Dimensia pada Lansia dengan Senam Otak di Posyandu Mawar Agung. *Jurnal Kreativitas Pengabdian Kepada Masyarakat (Pkm)*, 5(10), 3494–3503. <https://doi.org/10.33024/jkpm.v5i10.7224>

Tariot, P. N., Braeckman, R., & Oh, C. (2022). Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. *Journal of Alzheimer's Disease*, 90(1), 161–172. <https://doi.org/10.3233/JAD-220530>

Tu, H., Zhou, S., & Lin, J. (2025). Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer's Disease. *British Journal of Hospital Medicine*, 86(6), 1–15.

Xia, Y., Yassi, N., Raniga, P., Bourgeat, P., Desmond, P., Doecke, J., ... Salvado, O. (2020). Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. *Journal of Alzheimer's Disease*, 78(1), 321–334. <https://doi.org/10.3233/JAD-200419>

Yang, X., & Chen, Q. (2020). Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia. *Experimental and Therapeutic Medicine*, 21(1), 1–1. <https://doi.org/10.3892/etm.2020.9442>

Zubiagirre, U., Ibarondo, O., Larrañaga, I., et al. (2024). Comorbidity and household income as mediators of gender inequalities in dementia risk: a real-world data population study. *BMC Geriatrics*, 24, 209. <https://doi.org/10.1186/s12877-024-04770-3>